{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"31.2","value":"12.0"}]}],"title":"By cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.3","upperLimit":"72.2","value":"52.0"}]}],"title":"By cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.9","upperLimit":"75.6","value":"56.0"}]}],"title":"By cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.5","upperLimit":"82.0","value":"64.0"}]}],"title":"By cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"85.1","value":"68.0"}]}],"title":"By cycle 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"85.1","value":"68.0"}]}],"title":"By cycle 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"}]}],"title":"By cycle 36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"}]}],"title":"By cycle 48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"}]}],"title":"By cycle 66"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"by 3, 6, 9, 12, 24, 36, 48, 66 cycles (1 cycle = 28 days)","title":"MMR Rate by Time Points in Newly Diagnosed Ph+ CML-CP Patients","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}